dc.contributor | Universidade Estadual Paulista (UNESP) | |
dc.creator | Pinheiro, O. L. | |
dc.creator | Cavagna, M. | |
dc.creator | Baruffi, RLR | |
dc.creator | Mauri, A. L. | |
dc.creator | Petersen, C. | |
dc.creator | Franco, J. G. | |
dc.date | 2014-05-20T13:35:07Z | |
dc.date | 2016-10-25T16:52:36Z | |
dc.date | 2014-05-20T13:35:07Z | |
dc.date | 2016-10-25T16:52:36Z | |
dc.date | 2003-12-01 | |
dc.date.accessioned | 2017-04-05T20:27:49Z | |
dc.date.available | 2017-04-05T20:27:49Z | |
dc.identifier | Journal of Assisted Reproduction and Genetics. New York: Kluwer Academic/plenum Publ, v. 20, n. 12, p. 513-516, 2003. | |
dc.identifier | 1058-0468 | |
dc.identifier | http://hdl.handle.net/11449/12064 | |
dc.identifier | http://acervodigital.unesp.br/handle/11449/12064 | |
dc.identifier | 10.1023/B:JARG.0000013652.17193.38 | |
dc.identifier | WOS:000188532000006 | |
dc.identifier | http://dx.doi.org/10.1023/B:JARG.0000013652.17193.38 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/859728 | |
dc.description | Purpose: the objective of the present investigation was to determine implantation and pregnancy rates in patients undergoing ICSI and treated with beta(2)-adrenergic agonists, considering the uterine-relaxing action of these agents.Methods: A total of 225 women undergoing ICSI at the Center for Human Reproduction, Sinha Junqueira Maternity Foundation, entered the study. Patient participation in each group was random, by drawing lots, using a randomization table previously elaborated for the study (2:2:1). The group I (90 women) received 10 mg of terbutaline daily for 15 days starting on the day of oocyte retrieval; group II (90 women) received 20 mg of ritodrine daily during the same period of time as group I; group III (45 patients) received no treatment and was used as control. The evaluation was interrupted in 3 patients of group I and in 30 patients of group II because of a high incidence of side effects.Results: Pregnancy, implantation, and miscarriage rates were not significantly different (p>0.05) between the three groups: 29.88%, 13.25%, and 26.9% for group I; 33.33%, 17.5%, and 10.0% for group II; 28.88%, 15.07%, and 15.38% for group III, respectively.Conclusions: the results of this study do not support the routine use of beta(2)-adrenergic agonists during the peri-implantation period in assisted reproductive technology cycles. | |
dc.language | eng | |
dc.publisher | Kluwer Academic/plenum Publ | |
dc.relation | Journal of Assisted Reproduction and Genetics | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | ICSI | |
dc.subject | implantation rates | |
dc.subject | ritodrine | |
dc.subject | terbutaline | |
dc.subject | uterine contractility | |
dc.title | Administration of beta(2)-adrenergic agonists during the peri-implantation period does not improve implantation or pregnancy rates in intracytoplasmic sperm injection (ICSI) cycles | |
dc.type | Otro | |